Patent ID: 8715667

Claim:
A method of treating a cancer patient, said method comprising: a) providing a paraffin-embedded tissue section of cancerous tissue from a patient having melanoma breast cancer, lung cancer, esophageal cancer, stomach cancer, cancer of the larynx, kidney cancer or cervical cancer and detecting TLR3 in said paraffin-embedded cancerous tissue section with a monoclonal antibody that specifically binds to TLR3 in paraffin-embedded cancerous tissue sections, said monoclonal antibody comprising: i) variable light chain region CDRs: KSSQSLLDSDGKTYLN (SEQ ID NO:5; CDR1); LVSKLDS (SEQ ID NO:6; CDR2); and WQGIHLPYT (SEQ ID NO:7; CDR3) and variable heavy chain region CDRs: YTFTNYGMN (SEQ ID NO:8; CDR1); NANTGEPTYAEEFKG (SEQ ID NO:9; CDR2); and DYDY (SEQ ID NO:10; CDR3); or ii) variable light chain region CDRs: KSSQSLLDSDGKTYLN (SEQ ID NO:5; CDR1); LVSKLDS (SEQ ID NO:6; CDR2); and WQGIHLPYT (SEQ ID NO:7; CDR3) and variable heavy chain region CDRs: KASGYTFTNYGMN (SEQ ID NO:11; CDR1); NANTGEPTYAEEFKG (SEQ ID NO:9; CDR2); and DYDY (SEQ ID NO:10; CDR3); and b) treating a cancer patient positive for the presence of TLR3 in said paraffin-embedded cancerous tissue section by administering a TLR3 ligand to said cancer patient.